Sugi Predict

Sugi Predict / Targets / RPA3

RPA3

Replication protein A 14 kDa subunit · P35244 · RPA3 on Sugi Atlas →

0 patent compounds predicted against RPA3, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to RPA3 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Clinical and Pharmacoeconomic Assessment of CDK4/6 Inhibitors for Treatment of Breast Cancer in Egypt PHASE4COMPLETED
Trial of Topotecan With VX-970 (M6620), an ATR Kinase Inhibitor, in Small Cell Cancers and Extrapulmonary Small Cell Cancers PHASE1/PHASE2COMPLETED
I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers PHASE1/PHASE2NOT_YET_RECRUITING
Study to Evaluate IMP9064 as a Monotherapy or in Combination in Patients With Advanced Solid Tumors PHASE1/PHASE2RECRUITING
M7824 and Topotecan or Temozolomide in Relapsed Small Cell Lung Cancers PHASE1/PHASE2COMPLETED
A Phase 1/2 Trial of SRA737 in Subjects With Advanced Cancer PHASE1/PHASE2COMPLETED
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies PHASE1/PHASE2RECRUITING
Pembrolizumab and Olaparib Treatment of Extensive Small Cell Lung Cancer (ES-SCLC) PHASE2RECRUITING
A Phase 1/2 Trial SRA737 in Combination With Gemcitabine and Cisplatin or Gemcitabine Alone in Advanced Cancer Subjects PHASE1/PHASE2COMPLETED
Olaparib in Men With High-Risk Biochemically-Recurrent Prostate Cancer Following Radical Prostatectomy, With Integrated Biomarker Analysis PHASE2ACTIVE_NOT_RECRUITING
Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors PHASE1COMPLETED
Safety Study of ABT-888 Plus Topotecan Hydrochloride to Treat Patients With Solid Tumors and Lymphomas PHASE1COMPLETED
A Phase I Trial of SHR3162 in Subjects With Advanced Solid Tumors PHASE1COMPLETED
AZD2281 and Cisplatin Plus Gemcitabine to Treat Solid Tumor Cancers PHASE1COMPLETED
A Phase I Study of ABT-888, an Oral Inhibitor of Poly(ADP-ribose) Polymerase and Temozolomide in Children With Recurrent/Refractory CNS Tumors PHASE1COMPLETED
AZD1775 for Advanced Solid Tumors PHASE1COMPLETED
ABT-888 Plus Metronomic Cyclophosphamide to Treat Cancer PHASE1COMPLETED
Effect of Adenovirus E1A Oncogene on DNA Replication Dynamics nanUNKNOWN
DNA Damage & Repair Proteins In Patients With Atherosclerotic Coronary Artery Disease nanCOMPLETED
Telomeres Length in Israeli Fibrotic ILD Patients nanENROLLING_BY_INVITATION
DNA Repair Genes and Outcomes in Patients With Stage III NSCLC nanUNKNOWN
A Proof of Concept Study for the DNA Repair Driven by the Mesenchymal Stem Cells in Critical COVID-19 Patients nanCOMPLETED
Study of the Effect of Innate on the Inflammatory Response to Endotoxin nanRECRUITING
Unusual Infiltrative Patterns of Malignant Cells in Endometrial Carcinoma and Immunohistochemical Expression of P53 nanUNKNOWN
Telomere Repair Gene Mutation in Inflammatory Bowel Disease nanCOMPLETED
The Genetic and the Functional Study of DNA Repair System and the Susceptibility to Rheumatoid Arthritis nanCOMPLETED
Application of Genetic Polymorphisms of DNA Repair in The Prediction of Prostate Cancer Susceptibility and Its Clinical Outcome nanUNKNOWN
Hypofractionated Protontherapy in Chordomas and Chondrosarcomas of the Skull Base nanRECRUITING
Susceptibility to Infections in Ataxia Telangiectasia nanCOMPLETED
Identifying Genes and Mutations Underlying Retinitis Pigmentosa and Allied Diseases nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a RPA3 binder may also engage these)

ProteinNameSimilarity
Q9CQ71 — 0.996 Q9CQ71 →
Q9LXK1 — 0.974 Q9LXK1 →
Q9SDK9 — 0.973 Q9SDK9 →
Q6NLG7 — 0.968 Q6NLG7 →
I0IUP3 — 0.962 I0IUP3 →
Q6GM65 — 0.962 Q6GM65 →
Q9UJA3 — 0.960 Q9UJA3 →
Q0WW26 — 0.959 Q0WW26 →
Q6NME7 — 0.959 Q6NME7 →
P53620 — 0.958 P53620 →
P51660 — 0.957 P51660 →
A1DFN6 — 0.957 A1DFN6 →
Q5F310 — 0.956 Q5F310 →
Q9H1D9 — 0.956 Q9H1D9 →
P15927 — 0.956 P15927 →
Q3SZ19 — 0.956 Q3SZ19 →
Q9SF37 — 0.955 Q9SF37 →
F4IDS7 — 0.955 F4IDS7 →
Q9ZT87 — 0.955 Q9ZT87 →
Q9I8E6 — 0.955 Q9I8E6 →
P17571 — 0.955 P17571 →
Q9QXK3 — 0.955 Q9QXK3 →
D3ZVK1 — 0.955 D3ZVK1 →
Q5R981 — 0.955 Q5R981 →
Q9PUE4 — 0.955 Q9PUE4 →
Q99MH9 — 0.954 Q99MH9 →
Q9CWF6 — 0.954 Q9CWF6 →
Q5RC43 — 0.954 Q5RC43 →
PLAA Phospholipase A-2-activating protein 0.954 landscape →
Q08DS7 — 0.953 Q08DS7 →